Progress in postoperative adjuvant chemoradiotherapy for extrahepatic cholangiocarcinoma

doi:10.3877/cma.j.issn.1674-0793.2018.02.017

Abstract

Abstract:

Extrahepatic cholangiocarcinoma (ECC) is highly malignant. Even radical resection is performed in the early stage, ECC patients still have a high recurrence rate, with low overall survival. In recent years, clinical trials of postoperative adjuvant therapy have been carried out gradually. Adjuvant chemotherapy or combined chemoradiotherapy based on gemcitabine and fluorouracil have been shown beneficial for ECC patients after resection, prolonging the total survival of patients. However, the existing adjuvant therapy protocols are different, and there is no standard adjuvant therapy to recommend. This review discusses the status and main measures of postoperative adjuvant therapy for ECC, combined with the latest published findings.

Key words: Bile duct neoplasms, Neoadjuvant therapy, Gemcitabine, Fluorouracil

Fengzhou Du, Ning Zhang, Xiaodong He, Yuzhi Zuo, Yuan Xu, Qiang Qu. Progress in postoperative adjuvant chemoradiotherapy for extrahepatic cholangiocarcinoma[J]. Chinese Archives of General Surgery(Electronic Edition), 2018, 12(02): 135-138.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2018.02.017

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2018/V12/I02/135

References 25

[1]	Jung SJ, Woo SM, Park HK, et al. Patterns of initial disease recurrence after resection of biliary tract cancer[J]. Oncology, 2012, 83(2): 83-90.
[2]	陶连元，何小东，高飞, 等. 肝外胆管癌的临床病理与预后分析[J]. 肝胆外科杂志, 2011, 19(4): 251-253.
[3]	Takada T, Amano H, Yasuda H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase Ⅲ multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma[J]. Cancer, 2002, 95(8): 1685-1695.
[4]	Neoptolemos JP, Moore MJ, Cox TF, et al. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial[J]. JAMA, 2012, 308(2): 147-156.
[5]	Horgan AM, Amir E, Walter T, et al. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis[J]. J Clin Oncol, 2012, 30(16): 1934-1940.
[6]	Hoehn RS, Wima K, Ertel AE, et al. Adjuvant chemotherapy and radiation therapy is associated with improved survival for patients with extrahepatic cholangiocarcinoma[J]. Ann Surg Oncol, 2015, 22 Suppl 3: S1133-S1139.
[7]	McNamara MG, Walter T, Horgan AM, et al. Outcome of adjuvant therapy in biliary tract cancers[J]. Am J Clin Oncol, 2015, 38(4): 382-387.
[8]	Yang H, Zhou J, Wei X, et al. Survival outcomes and progonostic factors of extrahepatic cholangiocarcinoma patients following surgical resection: adjuvant therapy is a favorable prognostic factor[J]. Mol Clin Oncol, 2014, 2(6): 1069-1075.
[9]	Mizuno T, Ebata T, Yokoyama Y, et al. Adjuvant gemcitabine monotherapy for resectable perihilar cholangiocarcinoma with lymph node involvement: a propensity score matching analysis[J]. Surg Today, 2017, 47(2): 182-192.
[10]	NCCN Clinical Practice Guidelines in Oncology-Hepatobiliary Cancers, Version 1.2017[DB/OL]. URL
[11]	国际肝胆胰学会中国分会，中华医学会外科学分会肝脏外科学组. 胆管癌诊断与治疗——外科专家共识[J]. 临床肝胆病杂志, 2015, 31(1): 12-16.
[12]	Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J]. N Engl J Med, 2010, 362(14): 1273-1281.
[13]	Kobayashi S, Nagano H, Sakai D, et al. Phase Ⅰ study of adjuvant gemcitabine or S-1 in patients with biliary tract cancers undergoing major hepatectomy: KHBO1003 study[J]. Cancer Chemother Pharmacol, 2014, 74(4): 699-709.
[14]	Kainuma O, Miura F, Furukawa D, et al. Feasibility and efficacy of gemcitabine plus cisplatin combination therapy after curative resection for biliary tract cancer[J]. J Hepatobiliary Pancreat Sci, 2015, 22(11): 789-794.
[15]	Yamanaka K, Hatano E, Kanai M, et al. A single-center analysis of the survival benefits of adjuvant gemcitabine chemotherapy for biliary tract cancer[J]. Int J Clin Oncol, 2014, 19(3): 485-489.
[16]	Stein A, Arnold D, Bridgewater J, et al. Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase Ⅲ trial[J]. BMC Cancer, 2015, 15: 564.
[17]	Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials[J]. Br J Cancer, 2007, 96(6): 896-902.
[18]	Primrose JN, Fox R, Palmer DH, et al. Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study[J]. J Clin Oncol, 2017, 35(15_suppl): 4006.
[19]	Wirasorn K, Ngamprasertchai T, Khuntikeo N, et al. Adjuvant chemotherapy in resectable cholangiocarcinoma patients[J]. J Gastroenterol Hepatol, 2013, 28(12): 1885-1891.
[20]	Gwak HK, Kim WC, Kim HJ, et al. Extrahepatic bile duct cancers: surgery alone versus surgery plus postoperative radiation therapy[J]. Int J Radiat Oncol Biol Phys, 2010, 78(1): 194-198.
[21]	Kim S, Kim SW, Bang YJ, et al. Role of postoperative radiotherapy in the management of extrahepatic bile duct cancer[J]. Int J Radiat Oncol Biol Phys, 2002, 54(2): 414-419.
[22]	Nelson JW, Ghafoori AP, Willett CG, et al. Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma[J]. Int J Radiat Oncol Biol Phys, 2009, 73(1): 148-153.
[23]	Hughes MA, Frassica DA, Yeo CJ, et al. Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct[J]. Int J Radiat Oncol Biol Phys, 2007, 68(1): 178-182.
[24]	Dover LL, Oster RA, McDonald AM, et al. Impact of adjuvant chemoradiation on survival in patients with resectable cholan-giocarcinoma[J]. HPB (Oxford), 2016, 18(10): 843-850.
[25]	Ben-Josef E, Guthrie KA, El-Khoueiry AB, et al. SWOG S0809: A Phase Ⅱ intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma[J]. J Clin Oncol, 2015, 33(24): 2617-2622.

Please choose a citation manager

Content to export